{"id":"lenvatinib-and-sorafenib","safety":{"commonSideEffects":[{"rate":"54%","effect":"Hypertension"},{"rate":"45%","effect":"Diarrhea"},{"rate":"44%","effect":"Fatigue"},{"rate":"43%","effect":"Nausea"},{"rate":"42%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL1289601","moleculeType":"Small molecule","molecularWeight":"426.86"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lenvatinib and Sorafenib are both multi-kinase inhibitors that work by blocking the activity of certain enzymes (kinases) involved in the growth and spread of cancer cells.","oneSentence":"Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:42:09.455Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"RCC (Renal Cell Carcinoma)"}]},"trialDetails":[{"nctId":"NCT07193316","phase":"","title":"Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-07-27","conditions":"Hepatocellular Carcinoma, Liver Cirrhosis","enrollment":38},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":"Hepatocellular Carcinoma","enrollment":732},{"nctId":"NCT07418138","phase":"","title":"Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation","status":"COMPLETED","sponsor":"Hu Liangshuo","startDate":"2015-01-01","conditions":"Liver Transplantation, Hepatocellular Carcinoma (HCC), Tyrosine Kinase Inhibitor","enrollment":484},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":557},{"nctId":"NCT05673824","phase":"PHASE2","title":"Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-01-03","conditions":"Nephrotoxicity","enrollment":76},{"nctId":"NCT07351513","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT03468426","phase":"PHASE1","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-07-05","conditions":"Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms","enrollment":252},{"nctId":"NCT05033522","phase":"PHASE2, PHASE3","title":"Immunotherapy for Advanced Liver Cancer","status":"SUSPENDED","sponsor":"Mirror Biologics, Inc.","startDate":"2023-08-01","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT05822752","phase":"PHASE2","title":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-09-21","conditions":"Hepatocellular Carcinoma","enrollment":130},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05873244","phase":"PHASE2","title":"CXD101 in Immunotherapy-related Liver Cancer","status":"RECRUITING","sponsor":"Stephen Chan Lam","startDate":"2023-08-21","conditions":"HCC","enrollment":44},{"nctId":"NCT06482086","phase":"PHASE2","title":"Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-06-01","conditions":"Locally Advanced Thyroid Gland Carcinoma","enrollment":75},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT04763408","phase":"","title":"A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-04-09","conditions":"Carcinoma, Hepatocellular","enrollment":335},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06363006","phase":"PHASE1","title":"Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-11","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT06041490","phase":"PHASE2","title":"Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09","conditions":"Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma","enrollment":88},{"nctId":"NCT03892577","phase":"","title":"Real-world Study for Patients With Advanced Hepatobiliary Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-07-01","conditions":"Objective Response Rate, Progression-free Survival, Overall Survival","enrollment":3000},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05489692","phase":"","title":"HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-09-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":43},{"nctId":"NCT05420922","phase":"","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-11-01","conditions":"Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy","enrollment":2000},{"nctId":"NCT01761266","phase":"PHASE3","title":"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2013-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":954},{"nctId":"NCT05135364","phase":"PHASE2","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","status":"UNKNOWN","sponsor":"Yue Han","startDate":"2021-11-05","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT04639284","phase":"","title":"Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-12-23","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04687163","phase":"PHASE3","title":"Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-30","conditions":"Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT03775395","phase":"PHASE3","title":"HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-12","conditions":"Hepatocellular Carcinoma","enrollment":250},{"nctId":"NCT03499626","phase":"PHASE1, PHASE2","title":"Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2017-05-05","conditions":"Advanced/ Metastatic Hepatocellular Carcinoma","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lenvatinib and Sorafenib","genericName":"Lenvatinib and Sorafenib","companyName":"Stephen Chan Lam","companyId":"stephen-chan-lam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases. Used for RCC (Renal Cell Carcinoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}